Acromegaly is a disfiguring and disabling illness which, when inadequately treated, reduces life expectancy. An implication of the ability to offer effective treatment is the increased onus on physicians of all sorts to ensure acromegaly is diagnosed and treated as early as possible. To this end, criteria for the diagnosis of acromegaly have been proposed in the consensus statement of Giustina et al. [1]. However, other data suggest that the proposed criteria are not rigorous enough and strict adherence to the guidelines would result in failure to diagnose a significant number of patients. A review of published experience suggests that the combination of a GH nadir during an oral glucose tolerance test of <0.25 µg/l plus a normal age-related insulin growth factor-I level makes the diagnosis of acromegaly extremely unlikely.

Keywords:
Acromegaly, Growth hormone, Diagnosis, Insulin-like growth factor-I
1.
Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Was J, Von Werder K, Melmed S: Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000;85:526–529.
2.
Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK: Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994;41:95–102.
3.
Bates AS, Van’t Hoff W, Jones JM, Clayton RN: An audit of outcome of treatment in acromegaly. Q J Med 1993;86:293–299.
4.
Orme SM, McNally RJ, Cartwright PE, for the United Kingdom Acromegaly Study Group: Mortality and cancer incidence in acromegaly: a retrospective cohort study. J Clin Endocrinol Metab 1998;83:2730–2734.
5.
Swearingen B, Barker FG, Katznelson L, Biller BMK, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT: Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3419–3426.
6.
Beauregard C, Truong U, Hardy J, Serri O: Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 2003;58:86–91.
7.
Holdaway IM, Rajasoorya CR, Gamble GD, Stewart AW: Long-term treatment outcome in acromegaly. Growth Horm IGF Res 2003;13:185–192.
8.
Holdaway IM, Rajasoorya CR, Gamble GD: Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004;89:667–674.
9.
Rowles SV, Webb SM, Lee C, Shalet SM, Trainer PJ: Cross-sectional study of quality of life (QOL) in patients with acromegaly. Endocr Abstr 2002;4:62.
10.
van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO: Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001;358:1754–1759.
11.
Drange MR, Fram NR, Herman-Bonert V, Melmed S: Pituitary tumor registry: a novel clinical resource. J Clin Endocrinol Metab 2000;85:168–174.
12.
Freda PU, Post KD, Powell JS, Wardlaw SL: Evaluation of disease status with sensitive measures of GH secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab 1998;83:3808–3816.
13.
Freda PU, Nuruzzaman AT, Reyes CM, Sundeen RE, Post KD: Significance of ‘abnormal’ nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab 2004;89:495–500.
14.
Costa ACF, Rossi A, Martinelli CE, Machado HR, Moreira AC: Assessment of disease activity in treated acromegalic patients using sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure? J Clin Endocrinol Metab 2002;87:3142–3147.
15.
Serri O, Beauregard C, Hardy J: Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly. J Clin Endocrinol Metab 2004;89:658–661.
16.
Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF, Barkan AL: Acromegaly with apparently normal GH secretion: implication for diagnosis and follow-up. J Clin Endocrinol Metab 2002;87:3537–3542.
17.
Seth J, Ellis AR, Al-Sadie R: Serum GH measurements in clinical practice: an audit of performance from the UK National External Quality Assessment Scheme. Horm Res 1999;51(suppl 1):13–19.
18.
Ellis AR, Seth J, Al-Sadie R, Barth JH: An audit of the laboratory interpretation of GH response to insulin-induced hypoglycaemia in the assessment of short stature in children. Ann Clin Biochem 2003;40:239–243.
19.
Wieringa GE, Barth JH, Trainer PJ: GH assay standardisation: a biased view. Clin Endocrinol (Oxf) 2004;60:538–539.
20.
Granada ML, Sanmarti A, Lucas A, Salinas I, Carrascosa A, Foz M, Audi L: Assay-dependent results of immunoassayable spontaneous 24-h growth hormone secretion in short children. Acta Pædiatr Scand Suppl 1990;370:63–70.
21.
Bristow AF, Jespersen AM: The second international standard for somatropin (recombinant DNA-derived human growth hormone): preparation and calibration in an international collaborative study. Biologicals 2001;29:97–106.
22.
Melmed S: Confusion in clinical laboratory GH and IGF-I reports. Pituitary 1999;2:171–172.
23.
Brabant G, von zur Mühlen, Wüster C, Ranke MB, Kratzsch J, Kiess W, Ketelslegers JM, Wilhelmsen L, Hulthen L, Saller B, Mattsson A, Wilde J, Schemer R, Kann P: Serum insulin-like growth factor-I reference values for an automated chemiluminescence immunoassay system: results from multicenter study. Horm Res 2003;60(suppl 2):53–60.
24.
Chestnut RE, Quarmby V: Evaluation of total IGF-I assay methods using samples from type I and type II diabetic patients. J Immunol Methods 2002;259:11–24.
25.
Clemmons DR: Commercial assays available for insulin-like growth factor-I and their use in diagnosing growth hormone deficiency. Horm Res 2001;55:73–79.
26.
Rojdmark S, Brismar K: Decreased IGF-I bioavailability after ethanol abuse in alcoholics: partial restitution after short-term abstinence. J Endocrinol Invest 2001;24:476–482.
27.
Muller AF, Janssen JA, Lamberts SW, Bidlingmaier M, Strasburger CJ, Hofland L, van der Lely AJ: Effects of fasting and pegvisomant on the GH-releasing hormone and GH-releasing peptide-6 stimulated growth hormone secretion. Clin Endocrinol (Oxf) 2001;55:461–467.
28.
Parkinson C, Renehan AG, Ryder WD, O’Dweyer ST, Shalet SM, Trainer PJ: Gender and age influence the relationship between serum GH and IGF-I in patients with acromegaly. Clin Endocrinol (Oxf) 2002;57:363–370.
29.
Peacey SR, Toogood AA, Veldhuis JD, Thorner MO, Shalet SM: The relationship between 24 hour GH secretion and IGF-I in patients with successfully treated acromegaly: impact of surgery or radiotherapy. J Clin Endocrinol Metab 2001;86:259–266.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.